DOT-Gene-Editing-Header


New Frontiers in Gene Editing will bring together experts from all aspects of basic science and clinical research to talk about how and where gene editing can be best applied. What are the different tools that can be used for gene editing, and what are their strengths and limitations? How does the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system, compare to Transcription Activator-like Effector Nucleases (TALENs), zinc finger nucleases (ZFNs) and other systems and where are they being used? Scientists and clinicians from pharma/biotech as well as from academic and government labs will share their experiences leveraging the utility of gene editing for functional screening, disease modeling, and for creating cell and viral therapies.

Preliminary Agenda


FUNCTIONAL SCREENING USING GENE EDITING

FEATURED PRESENTATION: Gene Editing and Gene Silencing with CRISPR-Based Systems

Bruce R. Conklin M.D., Investigator, Roddenberry Center for Stem Cell Biology and Medicine, Gladstone Institutes and Professor, Division of Genomic Medicine University of California, San Francisco

Latest Approaches to Genetic Screens with CRISPR Technology

John Doench, Ph.D., Research Scientist, Broad Institute of Harvard and MIT

Assay Development for Phenotypic Screening: CRISPR-mediated Knockout, Knockdown and Sensor Cell Lines

Melissa G. Mendez, Ph.D., Postdoctoral Fellow, Laboratory of Assay Development & Screening Technology (ADST), National Center for Advancing Translational Sciences, NIH


BUILDING IN VIVO MODELS FOR DRUG DISCOVERY

Genome Editing Animal Models in Drug Discovery

Myung Shin, Ph.D., Principal Scientist, Biology-Discovery, Genetics and Pharmacogenomics, Merck Research Laboratories

In vivo Cancer Modeling and Genetic Screening Using CRISPR/Cas9

Sidi Chen, Ph.D., Postdoctoral Fellow, Laboratories of Dr. Phillip A. Sharp and Dr. Feng Zhang, Koch Institute for Integrative Cancer Research at MIT and Broad Institute of Harvard and MIT

Inducible Genome Editing for Disease Modeling

Lukas Dow, Ph.D., Assistant Professor of Biochemistry in Medicine, Department of Medicine, Hematology and Medical Oncology, Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College

In vivo Genome Editing Using Staphylococcus aureus Cas9

Fei Ann Ran, Ph.D., Post-Doctoral Fellow, Laboratory of Dr. Feng Zhang, Broad Institute and Junior Fellow, Harvard Society of Fellows


TOWARDS A THERAPEUTIC ENDPOINT

Going Native: Exploiting Endogenous CRISPR-Cas Systems for Genome Engineering

Chase Beisel, Ph.D., Assistant Professor, Department of Chemical & Biomolecular Engineering, North Carolina State University

Therapeutic Genome Editing for Blood Diseases

Matthew Porteus, M.D., Ph.D., Associate Professor, Pediatrics, Stanford University School of Medicine



For more details on the conference, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
E: tkoppal@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

DOT Hub Icon

2014 Discovery on Target Brochure  


IPR_Micrombiome 


2014 BROCHURE 

 PREMIER SPONSORS 

Cellecta 

Molecular Sensing 

Rosa Drug Development Advisors
 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


Westin Boston Waterfront

HOTEL & TRAVEL 

Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
617.426.2000